ArticlemBio2021
Secondary Metabolites from Food-Derived Yeasts Inhibit Virulence of Candida albicans.
Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Biofilm overproduction enhances gastrointestinal stress tolerance and intestinal fitness inGut microbes · 2026Article
- Harnessing Probiotics to Combat Acquired Resistance in Candida auris: Emerging Mechanisms and Formulation Strategies.Probiotics and antimicrobial proteins · 2026Review
- Saccharomyces cerevisiae reduces vulvovaginal candidiasis severity through modulation of fungal pathogenicity and inflammatory responses.Nature communications · 2026Article
- Saccharomyces cerevisiae 48338 Suppresses Antibiotic-Induced Clostridioides difficile Infection in a Murine Model.Probiotics and antimicrobial proteins · 2026Article
- Article
- Biotherapeutic Potential of Probiotic YeastIndian journal of microbiology · 2025Article
- Functional evaluation of synbiotic combination ofCurrent research in food science · 2025Article
- Conserved signaling modules regulate filamentous growth in fungi: a model for eukaryotic cell differentiation.Genetics · 2024Review
- Anti-Cariogenic Effects ofPharmaceutics · 2024Article
- Genetic basis for probiotic yeast phenotypes revealed by nanopore sequencing.G3 (Bethesda, Md.) · 2023Article
- Potential functions of the shared bacterial taxa in the citrus leaf midribs determine the symptoms of Huanglongbing.Frontiers in plant science · 2023Article
- Tyrosol induces multiple drug resistance in yeastFrontiers in microbiology · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
A sparse number of available antifungal drugs, therapeutic side effects, and drug resistance are major challenges in current antifungal therapy to treat Candida albicans-associated infections. Here, we describe two food-derived yeasts, Saccharomyces cerevisiae and Issatchenkia occidentalis, that inhibit virulence traits of C. albicans, including hyphal morphogenesis, biofilm formation, and adhesion to intestinal epithelial cells. These yeasts also protect the model host Caenorhabditis elegans from C. albicans infection. We demonstrate that the protective activity is primarily retained in the secretome of the beneficial yeasts, and the protection they provide as a physical barrier is negligible. S. cerevisiae
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.